Molecular Partners AG
SIX:MOLN
Molecular Partners AG
SIX:MOLN
Price:
3.51
CHF
-1.96%
Market Closed
Market Cap:
CHf141.7m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
E
|
Enservco Corp
AMEX:ENSV
|
US |
|
Cham Swiss Properties AG
F:4U3
|
CH |
|
Sodexo SA
OTC:SDXAY
|
FR |
Molecular Partners AG
Stock-Based Compensation
Last
Value
3 Years
3Y
CAGR
5 Years
5Y
CAGR
10 Years
10Y
CAGR
|
See Also
Molecular Partners AG
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Stock-Based Compensation
$72.5m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
2%
|
CAGR 10-Years
35%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Stock-Based Compensation
CHf5.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-6%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Stock-Based Compensation
CHf5.9m
|
CAGR 3-Years
-39%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Stock-Based Compensation
CHf949.6k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Stock-Based Compensation
CHf297k
|
CAGR 3-Years
-39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
No Stocks Found
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
MOLN
Intrinsic Value
7.24
CHF
Undervaluation 52%
